Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 670,429 | 696,989 | 630,145 | 560,841 | 545,632 |
| Receivables | 230,109 | 178,417 | 172,121 | 137,608 | 80,931 |
| Inventories | 367,906 | 341,154 | 353,034 | 344,398 | 308,750 |
| TOTAL | $1,313,587 | $1,254,706 | $1,189,684 | $1,081,797 | $970,787 |
| Non-Current Assets | |||||
| PPE Net | 159,078 | 165,726 | 118,952 | 106,189 | 97,393 |
| Investments And Advances | 27,575 | 36,800 | 33,083 | 39,621 | 43,128 |
| Intangibles | 4,318 | 4,198 | 4,374 | 4,302 | 4,118 |
| Other Non-Current Assets | 840,080 | 12,298 | 3,694 | 3,078 | 2,799 |
| TOTAL | $1,031,051 | $219,022 | $160,103 | $153,190 | $147,438 |
| Total Assets | $2,344,638 | $1,473,728 | $1,349,787 | $1,234,986 | $1,118,225 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 597,557 | 550,462 | 563,738 | 524,857 | 516,173 |
| Accounts payable and accrued liabilities | 91,979 | 102,569 | 91,877 | 106,389 | 88,884 |
| Other current liabilities | 620,092 | 549,606 | 495,604 | 429,359 | 326,169 |
| TOTAL | $1,318,763 | $1,209,909 | $1,153,101 | $1,061,412 | $932,883 |
| Non-Current Liabilities | |||||
| Long Term Debt | 451,899 | 435,876 | 387,337 | 374,827 | 376,428 |
| Other Non-Current Liabilities | 2,852 | 1,271 | 809 | 786 | 729 |
| TOTAL | $454,751 | $448,034 | $400,162 | $386,506 | $385,304 |
| Total Liabilities | $1,773,514 | $1,657,943 | $1,553,264 | $1,447,918 | $1,318,187 |
| Shareholders' Equity | |||||
| Common Shares | 9,808 | 9,416 | 9,683 | 9,321 | 8,625 |
| Retained earnings | -2,439,490 | -3,055,219 | -3,152,267 | -3,026,928 | -2,799,774 |
| Other shareholders' equity | 1,484 | -2,076 | -1,573 | 260 | 1,715 |
| TOTAL | $571,124 | $-184,216 | $-203,476 | $-212,932 | $-199,962 |
| Total Liabilities And Equity | $2,344,638 | $1,473,727 | $1,349,788 | $1,234,986 | $1,118,225 |